Sinotau Cloud Pharmaceutical is a subsidiary of Sinotau Pharmaceutical Group and it is responsible for the promotion and sales of radiopharmaceuticals.
Sinotau Cloud obtained MIBI's marketing and distribution rights from HTA's for 99mTc-MIBI to promote the development of a comprehensive diagnosis and treatment model combining nuclear medicine and cardiology for myocardial perfusion imaging.
Currently there is still a gap between the development level of China's nuclear medicine industry and the international status. We take this opportunity to contribute to Chinese patients by promoting novel radiopharmaceuticals for treatment and diagnosis of cardiovascular, neurological and oncological diseases. As a result of this initiative doctors in China will have access to suitable and effective diagnosis and treatment tools.